<DOC>
	<DOCNO>NCT01764646</DOCNO>
	<brief_summary>RATIONALE : It yet know whether extreme hypofractionation equally safe effective standard radiation therapy treat prostate cancer . PURPOSE : This protocol present randomised phase II study aim investigate tolerance disease control extreme hypofractionated Radiation Therapy prostate cancer .</brief_summary>
	<brief_title>Hypofractionated Radiation Therapy Prostate Cancer</brief_title>
	<detailed_description>This protocol present randomised phase II study aim investigate tolerance disease control extreme hypofractionated RT prostate cancer deliver 5 x 7.25 Gy = 36.25 Gy two alternative time schedule : either 9 day ( study A ) , 28 day once-a-week , week-day ( study B ) . The total dose fractionation schedule choose base assumption isoeffectivity regard potential late rectal effect expect maximum equivalent dose 74 Gy 2 Gy fraction assume alpha/beta = 3 Gy rectum . In arm , prescribe dose per fraction urethra surround transitional zone drop 7.25 Gy 6.5 Gy simultaneous integrate boost ( SIB ) technique . A dose 5 x 6.5 Gy equivalent 31 x 2 Gy assume alpha/beta = 3 Gy urethra equivalent 37 x 2 Gy assume alpha/beta = 1.5 Gy microscopic tumour foci transitional zone surround urethra . The two treatment regimen choose object separate phase I-II study cover protocol perform parallel participate centre . Randomised assignment either two study introduce avoid selection bias treatment assignment within centre . OBJECTIVES : Primary - To determine risk urinary , rectal sexual acute late toxicity rate patient receive two different time schedule extreme hypofractionated radiation therapy • Secondary - To determine Quality life ( EORTC QLQ-C30 , Prostate cancer module EORTC QLQ-PR25 ) patient receive two different time schedule extreme hypofractionated radiation therapy - To determine rate local failure - To determine two study arm biochemical disease-free survival bDFS rate - To determine two study arm metastases-free survival rate - To determine two study arm disease-specific survival rate OUTLINE : This multicenter study . Patients undergo extreme hypofractionated radiation therapy prostate cancer deliver 5 x 7.25 Gy = 36.25 Gy two alternative time schedule : Experimental Arm A : Over 9 day . Experimental Arm B : Over 28 day once-a-week , week-day . All patient follow least 18 month contribute analysis main endpoint study . With reference secondary endpoint , follow-up extend 10 year . Stopping rule : In order avoid exposure patient treatment may unsafe , acute GI GU toxicity continuously monitor purpose assist decision possibly interrupt recruitment case alarm frequency.To purpose , procedure Ivanova et al. , 2005 apply .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age : &gt; 18 WHO performance status ≤ 2 Any patient prophylactic lymph node irradiation require , i.e . risk nodal microscopic involvement ≤ 20 % ( accord Roach et al ( 25 ) : `` N+ ( % ) = ( Gleason score 6 ) x 10 + 2/3 PSA diagnosis ) '' Tstage : cT1cT3a . Previous TURP allow provide least 8 week interval radiotherapy . Combined hormonal treatment ( Neoadjuvantconcomitant androgen deprivation , AD , 6 month ) mandatory two follow tumour characteristic present : ≥cT2c , Gleason 4+3 , PSA &gt; 10 ng/ml , perineural invasion , and/or &gt; 1/3 positive biopsy . RT shall deliver 2 3 month ( +/ 1 week ) start AD accord follow chronologic sequence : 1 . Neoadjuvant AD 2 month ( 30 day bicalutamide 50mg qd , 3month slowreleasing LHRH analog start 15 day initiate bicalutamide ) . 2 . Randomization end neoadjuvant AD period ( 2 month start AD ) . 3 . Planning RT ( start within 1 month randomization ( i.e. , 2nd 3th month initiate AD ) Concomitant adjuvant HT 4 month ( second 3month slowreleasing LHRH analog injection ) . Inability obtain write informed consent Patient preference treat one rather treatment arm . WHO performance status &gt; 2 cT3b , cT4 Gleason score ≥8 Clinical N+ metastases workup N+ risk &gt; 20 % ( Roach algorithm ) Severe urinary obstructive symptom ( IPSS symptom index &gt; 19 ) Previous TURP le 8 week radiotherapy Previous prostate surgery TURP</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Radiation therapy</keyword>
</DOC>